HER2 testing: evolution and update for a companion diagnostic assay

Abstract

Human epidermal growth factor receptor 2 (HER2; encoded by ERBB2) testing has been a cornerstone of patient selection for HER2-targeted therapies, principally in breast cancer but also in several other solid tumours. Since the introduction of HercepTest as the original companion diagnostic for trastuzumab, HER2 assessment methods have evolved substantially, incorporating various testing modalities, from western blots, immunohistochemistry and fluorescence in situ hybridization, to early chromogenic quantitative methods and, probably in the future, fully quantitative methods. The advent of highly effective HER2-targeted antibody–drug conjugates with clinical activity at low levels of HER2 expression, such as trastuzumab deruxtecan, has necessitated the re-evaluation of HER2 testing, particularly for HER2-low tumours. In this Review, we provide an in-depth overview of the evolution of HER2 testing, the current clinical guidelines for HER2 testing across various solid tumours, challenges associated with current testing methodologies and the emerging potential of quantitative techniques. We discuss the importance of accurately defining HER2-low expression for therapeutic decision-making and how newer diagnostic approaches, such as quantitative immunofluorescence and RNA-based assays, might address the limitations of traditional immunohistochemistry-based methods. As the use of HER2-targeted therapies continues to expand to a wider range of tumour types, ensuring the precision and accuracy of HER2 testing will be crucial for guiding treatment strategies and improving patient outcomes. The development of companion diagnostic assays enabling the detection and quantification of HER2 expression and ERBB2 amplifications has provided an important early example that has informed the development of many companion diagnostics for the identification of other drug targets. However, the introduction of trastuzumab deruxtecan and, potentially, other novel antibody–drug conjugates has created the need for assays that are much more sensitive. In this Review, the authors describe the historical development of HER2 companion diagnostic assays in breast and other HER2-positive cancers and highlight the possible, future, more sensitive methods of HER2 detection and quantification that might provide the next generation of companion diagnostics.